MINNEAPOLIS--(BUSINESS WIRE)--Building upon the unprecedented wealth of data presented to an Advisory Committee to the U.S. Food and Drug Administration two weeks ago, Medtronic, Inc. (NYSE:MDT), today presented new 12-month data from the ENDEAVOR IV (E-IV) trial during a main-arena plenary session at the world’s leading scientific congress for interventional cardiologists, TCT 2007 (Transcatheter Cardiovascular Therapeutics), sponsored by the Cardiovascular Research Foundation.
